CITY OF INDUSTRY, Calif., Feb. 7 /PRNewswire-FirstCall/ -- U.S. BioDefense, Inc. announced today that part of a new $100 million gift by Mayor Michael Bloomberg that will go to stem cell research is the latest dissent from powerful sentiment in the New York Republican's own party. The donation was made anonymously to Johns Hopkins University but a source with knowledge of the details confirmed it came from Bloomberg, a graduate of the University and its former board chairman. For many years, he has been the major benefactor to its public health programs.
As part of a growing trend and sign of support for the stem cell field, the Stem Cell Research Institute, a subsidiary of U.S. BioDefense, Inc. is focused on raising $1 to $5 million dollars specifically to support ongoing stem cell research. On behalf of more than five million sufferers of neurodegenerative diseases worldwide, we are appealing for financial and collaborative support in furthering our stem cell research and commercialization efforts in collaboration with major universities. With further funding, support of our ongoing stem cell research can be developed into breakthrough therapies to find cures for diseases such as Parkinson's, spinal cord injury, diabetes, Alzheimer's, and ALS, amongst others.
With the Federal and State Government's lack of adequate grant funding, there's a very limited amount of money available to advance stem cell research. However there is an opportunity for philanthropists and investors to join us and participate directly in ongoing neurodegenerative disease research and commercialization efforts. Research now being conducted by Dr. Cyndi Chen, Director of Research at U.S. BioDefense is focused on the development and commercialization of a novel neural crest stem cell line which has the potential to differentiate into the necessary neurons for disease research.
Please contact us to discuss how you can help support neural crest stem cell research.
Forward-Looking Statements
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the U.S. BioDefense's financial performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to the U.S. BioDefense's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Information with respect to important factors that should be considered is contained in the U.S. BioDefense's Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The U.S. BioDefense does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.
Contact: U.S. BioDefense, Inc. David Chin (626)961-0562 info@usbiodefense.com
U.S. BioDefense, Inc.CONTACT: David Chin of U.S. BioDefense, Inc., +1-626-961-0562,info@usbiodefense.com
